A 1,2,3,4-tetrahydroquinoxaline derivative having a structure as represented by formula (I), preparation method therefor and application thereof. These compounds can be widely applied to preparation of drugs for treating one or more tumors, cancers, metabolic diseases, autoimmune diseases or disorders, and a new generation of RORγt agonist drugs is expected to be developed.

##STR00001##

An organic compound represented by [1], satisfying (i) and (ii), and represented by [2-1] or [2-2].

A-(B).sub.m  [1] (i) T.sub.1 of the unit A<T.sub.1 of the unit B, and (ii) HOMO-LUMO orbitals responsible for T.sub.1 transition are present in the unit A,

##STR00001## wherein R.sub.1 is selected from alkyl groups and the like, m denotes an integer of 1 or more and 5 or less, and n denotes an integer of 0 or more and 4 or less, the unit B is a fused ring with a partial structure represented by the general formula [3-1] or [3-2] or the like and is bonded to the unit A via a carbon atom, wherein X is selected from an oxygen atom, a sulfur atom, and the like, and the rings C to E independently denote a single ring and may have a deuterium atom or an alkyl group.

An organic compound represented by [1], satisfying (i) and (ii), and represented by [2-1] or [2-2].

A-(B).sub.m  [1] (i) T.sub.1 of the unit A<T.sub.1 of the unit B, and (ii) HOMO-LUMO orbitals responsible for T.sub.1 transition are present in the unit A,

##STR00001## wherein R.sub.1 is selected from alkyl groups and the like, m denotes an integer of 1 or more and 5 or less, and n denotes an integer of 0 or more and 4 or less, the unit B is a fused ring with a partial structure represented by the general formula [3-1] or [3-2] or the like and is bonded to the unit A via a carbon atom, wherein X is selected from an oxygen atom, a sulfur atom, and the like, and the rings C to E independently denote a single ring and may have a deuterium atom or an alkyl group.

The invention relates to compounds of Formula I″ ##STR00001##
wherein R, R.sup.1, R.sup.2, R.sup.3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.

The invention relates to compounds of Formula I″ ##STR00001##
wherein R, R.sup.1, R.sup.2, R.sup.3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.

Methods are disclosed of designing antibodies for a sandwich assay for a small molecule having a molecular weight of about 500 to about 2,000. The method comprises preparing a first antibody that binds to the small molecule, and preparing a second antibody that binds to the small molecule at a portion of the small molecule other than a portion to which the first antibody binds. The second antibody is prepared from an immunogen that comprises a predetermined portion of the small molecule. The antibodies may be employed in sandwich assays for the small molecule.

The invention relates to compounds of Formula I″

##STR00001##

wherein R, R.sup.1, R.sup.2, R.sup.3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.

The invention relates to compounds of Formula I″ ##STR00001##
wherein R, R.sup.1, R.sup.2, R.sup.3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.

To solve the problem that the existing non-aqueous electrolyte for a lithium ion battery cannot ensure the high-temperature storage performance and cycle performance at the same time, the invention provides a non-aqueous electrolyte for a lithium ion battery, comprising a solvent, a lithium salt and a compound represented by structural formula 1 and/or structural formula 2:

##STR00001##

Meanwhile, the invention also discloses a lithium ion battery comprising the non-aqueous electrolyte for a lithium ion battery. The non-aqueous electrolyte provided by the invention can effectively improve the cycle performance and high-temperature storage performance of lithium ion batteries.

The invention relates to compounds of Formula I″

##STR00001##

wherein R, R.sup.1, R.sup.2, R.sup.3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.